Sensus Healthcare and Megatop MTC are pleased to announce the SFDA approval of the SRT-100™ advanced superficial radiotherapy platform to be sold in China. This approval allows Megatop MTC to begin their sales and marketing initiatives in China immediately. Megatop has already ordered 9 systems to be delivered in 2012 to meet the existing demand. This is a continuation to the initial momentum started by Megatop MTC in Hong-Kong, where they sold and installed two SRT-100™ units at the Prince of Wales and Sanatorium hospitals.
“China is an important market. We are thrilled for the validation and acceptance of the SRT-100™ technology. There are unique applications for SRT treatment in the Chinese healthcare market and we are pleased to have Sensus recognized as a solution to those needs. We are excited to be working with our distribution partner, Megatop MTC, as we begin our sales and marketing initiatives and we thank and congratulate the authorities in China for allowing us the opportunity to serve their healthcare community.” stated Joe Sardano, President/CEO, Sensus Healthcare.
“The teamwork, persistence, and integrity of the SRT-100™ system allows us to reach this major milestone of gaining SFDA’s approval. Our success in Hong Kong over the past 2 years has already put us in good position to draw the attention of leading hospitals in China. The SRT-100™ is the only SFDA approved skin cancer treatment device in China.” stated George Shum, Managing Director of MMTC.
Rick Golin EVP of Sales, Radiation Oncology for Sensus Healthcare added: “Obtaining SFDA approval is a significant milestone for Sensus. Megatop, the exclusive Sensus distributor for China, spent a great deal of time and effort in gaining approval while working in concert with us.”
About Sensus Healthcare:
Sensus Healthcare specializes in making proven non-melanoma skin cancer solutions more accessible to patients. Our dedicated superficial radiation therapy (SRT) systems are designed specifically to provide an alternative to surgical procedures for basal cell and squamous cell carcinomas. Our mobile, compact SRT-100™ systems are used widely by oncologists and dermatologists to bring non-melanoma skin cancer treatment to more patients in more settings.
561-922-5808 Ext. 100